ORIGINAL RESEARCHInterrelationship of Sildenafil Treatment Effects on the Physiological and Psychosocial Aspects of Erectile Dysfunction of Mixed or Organic Etiology
Introduction
The inability to have or successfully complete intercourse can affect a man's quality of life and is associated with anxiety and loss of self-esteem [1]. Performance anxiety (anxiety about the ability to respond sexually) may always be present at some level in men with erectile dysfunction (ED). With each successive sexual failure, performance anxiety may escalate, further worsening sexual responsiveness and leading men to avoid future sexual interactions 1, 2.
Treating the functional (physiological) aspects of ED (erection hardness and erection maintenance) is one of the key steps in overcoming performance anxiety. The phosphodiesterase type 5 inhibitor (PDE5) sildenafil citrate (VIAGRA®, Pfizer Inc, New York, NY, USA) is a proven treatment for ED [3]. The impact of sildenafil on erectile function and erection hardness, and the resulting improvement in confidence, sexual relationship satisfaction, and the level of anxiety about the next intercourse attempt, were assessed in men with ED in a double-blind placebo-controlled (DBPC) trial of sildenafil at a fixed dose of 50 mg or 100 mg [4]. The effect of sildenafil on erection maintenance, indirectly (mediated through erection hardness) and directly, was previously estimated [5].
In follow up to the previous modeling of the relationships between the physiological aspects of the treatment of ED (i.e., hardness and maintenance), the main objective of the current report is to test the historical psychosocial paradigm of ED, which focuses on performance anxiety, by using mediation modeling to define the relationship of the physiological aspects (hardness and maintenance) and the associated psychosocial aspects (confidence, sexual relationship satisfaction, and performance anxiety) of ED.
Section snippets
Data Set
The data set, which was described previously [4], was derived from a multinational (Republic of Korea, Russian Federation, Spain, and Sweden), parallel-group, randomized (1:1:1), DBPC trial of fixed-dose sildenafil (100 or 50 mg, 8 weeks) with open-label (OL) extension of flexible-dose sildenafil (50 and 100 mg, 4 weeks). Medication was taken as needed for sexual activity but not more than once daily. Inclusion criteria were age ≥18 years; a clinical diagnosis of ED confirmed by a score ≤25 out
Results
The 288 men randomized to sildenafil 50 mg (N = 94), sildenafil 100 mg (N = 99), or placebo (N = 95) were similar in age (mean, 51 years; range, 20–65 years) and ethnicity (approximately two thirds white and one third Asian). Most had ED of organic or mixed etiology.
Discussion
There are many published reports of the effect of ED treatment on erection hardness, erection maintenance, and erectile function. It has also been demonstrated that psychosocial outcomes, including sexual confidence, can be improved by sildenafil or by other PDE5s 3, 17, 18, 19, 20, 21, 22, 23, 24. Furthermore, correspondence between scores on the EHS and scores on other ED-specific patient-reported outcomes (i.e., the IIEF, the Quality of Erection Questionnaire, the Sexual Experience
Potential conflicts of Interest
Dr Althof receives research support from Boehringer Ingelheim Corporation and Plethora, and is a consultant to Eli Lilly and Company, Boehringer Ingelheim Corporation, GlaxoSmithKline, Johnson & Johnson, Palatin Technologies, Pfizer Inc, and Plethora. Dr Althof is also a speaker for Eli Lilly and Company and Boehringer-Ingelheim.
Dr Berner is a consultant to Boehringer Ingelheim and Pfizer Inc. He received research grants or tuition fees from the Federal Ministry for Education and Research of
Category 1
- (a)
Conception and Design
Joseph C. Cappelleri; Andrew G. Bushmakin; Tara Symonds; Gabriel Schnetzler
- (b)
Acquisition of Data
Stanley E. Althof; Michael M. Berner; Irwin Goldstein; Hubert I.M. Claes; Joseph C. Cappelleri; Andrew G. Bushmakin; Tara Symonds; Gabriel Schnetzler
- (c)
Analysis and Interpretation of Data
Stanley E. Althof; Michael M. Berner; Irwin Goldstein; Hubert I.M. Claes; Joseph C. Cappelleri; Andrew G. Bushmakin; Tara Symonds; Gabriel Schnetzler
Category 2
- (a)
Drafting the Article
Stanley E. Althof; Michael M.
Acknowledgements
This study was sponsored by Pfizer Inc. Editorial support was provided by Deborah M. Campoli-Richards, BSPHA, RPh, of Complete Healthcare Communications, Inc., and was funded by Pfizer Inc.
References (29)
- et al.
Sildenafil citrate 100 mg starting dose in men with erectile dysfunction in an international, double-blind, placebo-controlled study: Effect on the sexual experience and reducing feelings of anxiety about the next intercourse attempt
J Sex Med
(2009) - et al.
Sildenafil treatment: Understanding its effects on erection maintenance and erection hardness
J Sex Med
(2010) - et al.
The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction
Urology
(1997) - et al.
Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function
Urology
(1999) - et al.
Validation of the Erection Hardness Score (EHS)
J Sex Med
(2007) - et al.
Quality of erections in men treated with flexible-dose sildenafil for erectile dysfunction: Multicenter trial with a double-blind, randomized, placebo-controlled phase and an open-label phase
J Sex Med
(2008) - et al.
Quality of erection questionnaire correlates: Change in erection quality with erectile function, hardness, and psychosocial measures in men treated with sildenafil for erectile dysfunction
J Sex Med
(2007) - et al.
Sildenafil citrate improves self-esteem, confidence, and relationships in men with erectile dysfunction: Results from an international, multi-center, double-blind, placebo-controlled trial
J Sex Med
(2006) - et al.
Comparison between sildenafil-treated subjects with erectile dysfunction and control subjects on the Self-Esteem And Relationship Questionnaire
J Sex Med
(2006) - et al.
Efficacy of vardenafil and influence on self-esteem and self-confidence in patients with severe erectile dysfunction
J Sex Med
(2007)
Vardenafil improves satisfaction rates, depressive symptomatology, and self-confidence in a broad population of men with erectile dysfunction
J Sex Med
Vardenafil improves sexual function and treatment satisfaction in couples affected by erectile dysfunction (ED): A randomized, double-blind, placebo-controlled trial in PDE5 inhibitor-naive men with ED and their partners
J Sex Med
Scoring Correspondence in Outcomes Related to Erectile Dysfunction Treatment on a 4-Point Scale (SCORE-4)
J Sex Med
The dual control model of male sexual response: A theoretical approach to centrally mediated erectile dysfunction
Neurosci Biobehav Rev
Cited by (28)
Digital Real-world Data Suggest Patient Preference for Tadalafil over Sildenafil in Patients with Erectile Dysfunction
2022, European Urology FocusCitation Excerpt :One probable reason for this preference is the higher flexibility gained by the significantly longer half-life compared with that of sildenafil [6,7]. This is supported by the studies of Rubio-Aurioles et al [13], Althof et al [23], and Tsujimura et al [24], which showed that routine and PRN tadalafil demonstrated great improvements in sexual self-confidence, time concerns, and spontaneity when compared with PRN sildenafil. We must acknowledge the limitations of this retrospective cross-sectional study without randomization.
Erectile dysfunction and adherence to antihypertensive therapy: Focus on β-blockers
2020, European Journal of Internal MedicineCitation Excerpt :On the other hand, improvements in erectile function were related with benefits in self-esteem and mood in men with ED. Importantly, use of PDE-5 inhibitors was associated with amelioration of self-confidence and esteem, sexual satisfaction, relationship status, psychological status, vitality, general health and depressive symptoms [54,55]. Of importance, ED not only affects the quality of life of the affected individual, but may also result in sexual and emotional impairment of the sexual partners [56].
Combination of psychological intervention and phosphodiesterase-5 inhibitors for erectile dysfunction: A narrative review and meta-analysis
2014, Journal of Sexual MedicineCitation Excerpt :As combined treatment seems a more promising treatment option than single treatment, such trials should be prioritized in order to come to stronger conclusions about the importance of such combinations. So far the working mechanism of the add‐on effect of PI is unclear, and various possible explanations should be tested [56,57]. The better outcome of the combined treatment compared with PDE‐5I use alone could be due to (i) better compliance with PDE5‐I regimen (medical explanation); (ii) a decrease in performance anxiety (psychological explanation [58]); or (iii) nonspecific elements of the PI.